thalidomide has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 58 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)." | 7.70 | [Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "St Vincent's Hospital Melbourne cautiously prescribes thalidomide as a treatment for recalcitrant dermatoses." | 3.71 | Thalidomide experience of a major Australian teaching hospital. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2002) |
| "Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)." | 3.70 | [Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000) |
| "Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal." | 2.77 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. ( Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M, 2012) |
| "Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE)." | 2.72 | Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice. ( Aikawa, NE; Bonfa, E; Heise, CO; Pasoto, SG; Romiti, R; Silva, CA; Yuki, EFN, 2021) |
| "Thalidomide has subsequently been reported to be effective in treating a number of dermatoses, including cutaneous lupus erythematosus." | 2.69 | American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. ( Duong, DJ; Gaspari, AA; Moxley, RT; Spigel, GT, 1999) |
| "Thalidomide has shown excellent results for severe cutaneous lupus erythematosus (CLE), but its prescription is limited by potentially severe adverse events." | 2.58 | Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( Arnaud, L; Barbaud, A; Cesbron, E; Chasset, F; Francès, C; Tounsi, T, 2018) |
| "Thalidomide and analogues are a class of immunomodulatory drugs or IMiDS." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "This paper reviews the latest treatments for cutaneous lupus erythematosus." | 2.42 | Update on the management of cutaneous lupus erythematosus. ( Callen, JP, 2004) |
| "Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry." | 1.62 | One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. ( Aikawa, NE; Arnone, M; Bonfa, E; Heise, CO; Kupa, LVK; Pasoto, SG; Pedrosa, TDN; Romiti, R; Silva, CAAD; Soares, R; Yuki, EFN, 2021) |
| "Psychiatric and personality disorders have been extensively documented in patients with systemic lupus erythematosus (SLE)." | 1.46 | High Prevalence of Personality Disorders in Skin-restricted Lupus Patients. ( Bonnefond, S; Collange, M; D'Incan, M; Jalenques, I; Labeille, B; Massoubre, C; Mulliez, A; Perrot, JL; Rondepierre, F; Schwan, R, 2017) |
| "Lenalidomide was well tolerated." | 1.46 | Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. ( Rabinovich, CE; Schanberg, LE; Wershba, EC; Wu, EY, 2017) |
| "Lenalidomide was effective for the treatment of CLE (particularly DLE) but not for the treatment of lupus panniculitis in this series." | 1.43 | Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. ( Davis, MD; Kindle, SA; Pittelkow, MR; Sciallis, GF; Wetter, DA, 2016) |
| "Clinical relapse was frequent (73%) and occurred between 3 and 24 weeks after withdrawal of thalidomide." | 1.42 | Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus? ( Baret, I; De Haes, P, 2015) |
| "Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE)." | 1.38 | Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. ( Braunstein, I; Goodman, NG; Kovarik, CL; Krathen, M; Luning Prak, E; Okawa, J; Rosenbach, M; Shah, A; Werth, VP, 2012) |
| "Clinical relapse was frequent (70%) and usually occurred 5 months after withdrawal or reduction of thalidomide." | 1.38 | Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. ( Castro-Marrero, J; Cortés-Hernández, J; Ordi-Ros, J; Torres-Salido, M; Vilardell-Tarres, M, 2012) |
| " The threshold neurotoxic dosage is lower than previously reported." | 1.35 | Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008) |
| "Thalidomide has been reported as an effective treatment in at least 200 cases of severe DLE." | 1.33 | [Thalidomide therapy for discoid lupus erythematosus]. ( Baum, S; Lyakhovisky, A; Salomon, M; Shpiro, D; Trau, H, 2006) |
| "Thalidomide is an anti-inflammatory agent and an immunomodulator that inhibits the production of tumor necrosis factor alpha." | 1.32 | Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. ( Fleischer, AB; Grummer, SE; Housman, TS; Jorizzo, JL; McCarty, MA; Sutej, PG, 2003) |
| "Its use in cutaneous lupus erythematosus is now well documented, although most groups favour high-dose regimes (200 mg twice daily), where side effects are common and may limit drug use." | 1.31 | Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus. ( Goodfield, MJ; Thomson, KF, 2001) |
| "Thalidomide is a potent anti-inflammatory drug in patients with SLE and cutaneous LE, possibly interacting with the recruitment of lymphocytes." | 1.31 | Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. ( Messer, G; Meurer, M; Plewig, G; Walchner, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.17) | 18.2507 |
| 2000's | 25 (43.10) | 29.6817 |
| 2010's | 23 (39.66) | 24.3611 |
| 2020's | 7 (12.07) | 2.80 |
| Authors | Studies |
|---|---|
| Rizvi, SK | 1 |
| Chong, BF | 1 |
| Sherman, MA | 1 |
| Srinivasalu, H | 1 |
| Kirkorian, AY | 1 |
| Cardis, MA | 1 |
| Tsiogka, A | 1 |
| Gerochristou, M | 1 |
| Agrogianni, A | 1 |
| Gregoriou, S | 1 |
| Rigopoulos, D | 1 |
| Kontochristopoulos, G | 1 |
| Wang, X | 2 |
| Li, M | 1 |
| Zeng, X | 1 |
| Wang, Q | 1 |
| Yuki, EFN | 2 |
| Silva, CA | 1 |
| Aikawa, NE | 2 |
| Romiti, R | 2 |
| Heise, CO | 2 |
| Bonfa, E | 2 |
| Pasoto, SG | 2 |
| Reymann, V | 1 |
| Bessis, D | 2 |
| Bergeret, B | 1 |
| Lipsker, D | 2 |
| Du-Thanh, A | 1 |
| Terrail, N | 1 |
| Dandurand, M | 1 |
| Dereure, O | 1 |
| Soares, R | 1 |
| Kupa, LVK | 1 |
| Arnone, M | 1 |
| Pedrosa, TDN | 1 |
| Silva, CAAD | 1 |
| Jalenques, I | 1 |
| Rondepierre, F | 1 |
| Massoubre, C | 1 |
| Bonnefond, S | 1 |
| Schwan, R | 1 |
| Labeille, B | 1 |
| Perrot, JL | 1 |
| Collange, M | 1 |
| Mulliez, A | 1 |
| D'Incan, M | 1 |
| Nutan, F | 1 |
| Ortega-Loayza, AG | 1 |
| Chasset, F | 3 |
| Tounsi, T | 1 |
| Cesbron, E | 2 |
| Barbaud, A | 2 |
| Francès, C | 6 |
| Arnaud, L | 2 |
| Jachiet, M | 1 |
| Cordel, N | 2 |
| Bouaziz, JD | 1 |
| Bagot, M | 1 |
| Bishnoi, A | 1 |
| Singh, V | 1 |
| Handa, S | 1 |
| Vinay, K | 1 |
| Groenen, PS | 1 |
| van Helmond, N | 1 |
| Chapman, KB | 1 |
| Dalm, VA | 1 |
| van Hagen, PM | 1 |
| Zattra, E | 1 |
| Stan, R | 1 |
| Russo, I | 1 |
| Lo Nigro, A | 1 |
| Peserico, A | 1 |
| Alaibac, M | 1 |
| Okon, L | 1 |
| Rosenbach, M | 2 |
| Krathen, M | 2 |
| Rose, M | 1 |
| Propert, K | 1 |
| Okawa, J | 2 |
| Werth, V | 1 |
| Baret, I | 1 |
| De Haes, P | 1 |
| Anyanwu, CO | 1 |
| Stewart, CL | 1 |
| Werth, VP | 5 |
| Hejazi, EZ | 1 |
| Kindle, SA | 1 |
| Wetter, DA | 1 |
| Davis, MD | 1 |
| Pittelkow, MR | 1 |
| Sciallis, GF | 1 |
| Wang, D | 1 |
| Chen, H | 1 |
| Wang, S | 1 |
| Zou, Y | 1 |
| Li, J | 1 |
| Pan, J | 1 |
| Ren, T | 1 |
| Zhang, Y | 1 |
| Chen, Z | 1 |
| Feng, X | 1 |
| Sun, L | 1 |
| Fennira, F | 1 |
| Soubrier, M | 1 |
| Petit, A | 1 |
| Wu, EY | 1 |
| Schanberg, LE | 1 |
| Wershba, EC | 1 |
| Rabinovich, CE | 1 |
| Kuhn, A | 2 |
| Aberer, E | 1 |
| Bata-Csörgő, Z | 1 |
| Caproni, M | 1 |
| Dreher, A | 1 |
| Gläser, R | 1 |
| Klötgen, HW | 1 |
| Landmann, A | 1 |
| Marinovic, B | 1 |
| Nyberg, F | 1 |
| Olteanu, R | 1 |
| Ranki, A | 1 |
| Szepietowski, JC | 1 |
| Volc-Platzer, B | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 1 |
| Sanchez, MR | 1 |
| Levis, WR | 1 |
| Ruland, V | 1 |
| Bonsmann, G | 1 |
| Chang, AY | 1 |
| Braunstein, I | 1 |
| Goodman, NG | 1 |
| Shah, A | 1 |
| Kovarik, CL | 1 |
| Luning Prak, E | 1 |
| Cortés-Hernández, J | 2 |
| Torres-Salido, M | 1 |
| Castro-Marrero, J | 1 |
| Vilardell-Tarres, M | 2 |
| Ordi-Ros, J | 2 |
| Ávila, G | 1 |
| Thomson, KF | 1 |
| Goodfield, MJ | 1 |
| Bohmeyer, J | 1 |
| Achenbach, A | 1 |
| Westenberger, M | 1 |
| Stadler, R | 1 |
| Crouch, RB | 1 |
| Foley, PA | 1 |
| Ng, JC | 1 |
| Baker, CS | 1 |
| Housman, TS | 1 |
| Jorizzo, JL | 1 |
| McCarty, MA | 1 |
| Grummer, SE | 1 |
| Fleischer, AB | 2 |
| Sutej, PG | 1 |
| Barete, S | 1 |
| Ayoub, N | 1 |
| Piette, JC | 2 |
| Pelle, MT | 1 |
| Briani, C | 2 |
| Zara, G | 3 |
| Rondinone, R | 3 |
| Della Libera, S | 1 |
| Ermani, M | 3 |
| Ruggero, S | 2 |
| Ghirardello, A | 2 |
| Zampieri, S | 2 |
| Doria, A | 3 |
| Callen, JP | 1 |
| Heath, M | 1 |
| Raugi, GJ | 1 |
| Cuadrado, MJ | 1 |
| Karim, Y | 1 |
| Sanna, G | 1 |
| Smith, E | 1 |
| Khamashta, MA | 2 |
| Hughes, GR | 2 |
| Groves, RW | 1 |
| Gambini, D | 1 |
| Carrera, C | 1 |
| Passoni, E | 1 |
| Muratori, S | 1 |
| Berti, E | 1 |
| Caputo, R | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Wenzel, J | 1 |
| Bieber, T | 1 |
| Uerlich, M | 1 |
| Tüting, T | 1 |
| Iaccarino, L | 1 |
| Toffanin, E | 1 |
| Sarzi-Puttini, P | 1 |
| Lyakhovisky, A | 1 |
| Baum, S | 1 |
| Shpiro, D | 1 |
| Salomon, M | 1 |
| Trau, H | 1 |
| Llambrich, A | 1 |
| Romero, D | 1 |
| Iranzo, P | 1 |
| Segura, S | 1 |
| Moreno, JA | 1 |
| Herrero, C | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Arienti, S | 1 |
| Stevens, RJ | 1 |
| Andujar, C | 1 |
| Edwards, CJ | 1 |
| Ames, PR | 1 |
| Barwick, AR | 1 |
| Rúa-Figueroa, I | 1 |
| Erausquin, C | 1 |
| Naranjo, A | 1 |
| Carretero-Hernández, G | 1 |
| Rodriguez-Lozano, C | 1 |
| De la Rosa, P | 1 |
| Duong, DJ | 1 |
| Spigel, GT | 1 |
| Moxley, RT | 1 |
| Gaspari, AA | 1 |
| Flageul, B | 1 |
| Wallach, D | 1 |
| Cavelier-Balloy, B | 1 |
| Bachelez, H | 1 |
| Carsuzaa, F | 1 |
| Dubertret, L | 1 |
| Calabrese, L | 1 |
| Walchner, M | 1 |
| Meurer, M | 1 |
| Plewig, G | 1 |
| Messer, G | 1 |
| Versapuech, J | 1 |
| Beylot-Barry, M | 1 |
| Doutre, MS | 1 |
| Beylot, C | 1 |
| McCauliffe, DP | 1 |
| Sbai, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus[NCT00633945] | 5 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus[NCT01408199] | Phase 4 | 15 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Cutaneous Lupus Area and Severity Index (CLASI); range of disease activity is 0-70. Lower scores reflect less activity. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 0 weeks | 6 weeks | 12 weeks | 52 weeks | |
| Lenalidomide | 21.4 | 10.8 | 8.6 | 5.3 |
Fatigue scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no fatigure and 10 to fatigue as bad as you can imagine. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 7.25 | 3.4 | 5.25 | 3 |
Itch scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no itch and 10 to itch as bad as you can imagine. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 4.0 | 1.2 | 2.25 | 0 |
CXCL10, an interferon-inducible chemokine, and immunophenotyping by immunostaining. Measurement of interferon-inducible genes from peripheral blood mononuclear cells before and after treatment. (NCT00633945)
Timeframe: 6 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| IFN score decrease | CD4 decrease | |
| Lenalidomide Nonresponder | 1 | 1 |
| Lenalidomide Responders | 4 | 4 |
Pain in skin was recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no pain and 10 to pain as bad as you can imagine. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 4.5 | 2 | 2.5 | 0.5 |
General skin scores were recorded by the patient on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 5.6 | 3.6 | 4.2 | 0.8 |
General skin scores were recorded on a 10 cm visual analogue scale at each visit. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 6 | 3 | 3.8 | 2 |
"Skindex function scores are scored 1-5 and then normalized to 100, with a higher score corresponding to a worse impression. The absence of function impact on QoL is scored as 20 (this is represented as a 1 on the 1-5 scale. The worst impact of function on QoL is 100. This is represented as a 5 on the 1-5 scale." (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 41.26 | 30.42 | 29.2 | 4.2 |
"Skindex symptoms scores are scored 1-5 and then normalized to 100, with a higher score corresponding to a worse impression. The absence of symptom impact on QoL is scored as 20 (this is represented as a 1 on the 1-5 scale. The worst impact of symptoms on QoL is 100. This is represented as a 5 on the 1-5 scale." (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 58.5 | 41.82 | 36.4 | 12.5 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
15 reviews available for thalidomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Retrospective S | 2021 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Hum | 2017 |
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Peripheral Nervous System Diseases | 2018 |
TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
Topics: Animals; Antibodies, Blocking; Clinical Trials as Topic; Drug Resistance; Drug-Related Side Effects | 2013 |
Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment.
Topics: Administration, Topical; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Cytokines; G | 2016 |
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murin | 2011 |
Treatment of cutaneous lupus.
Topics: Administration, Topical; Antimalarials; Calcineurin Inhibitors; Dapsone; Glucocorticoids; Humans; Im | 2011 |
Thalidomide in cutaneous lupus erythematosus.
Topics: Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Lupus Eryth | 2003 |
Update on the management of cutaneous lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antimalarials; Dermatologic Agents; Evidence-Based Medicine; Humans; Lupus | 2004 |
Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimalarials; Azathioprine; Cladrib | 2004 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
[Systemic treatment of cutaneous lupus erythematosus].
Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antimal | 2003 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Cutaneous lupus erythematosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Biopsy; Clofazimine; Dermatologic Agents; Di | 2001 |
4 trials available for thalidomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Topics: Administration, Oral; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule | 2014 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalid | 2012 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus.
Topics: Adult; Clinical Protocols; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Midd | 1999 |
39 other studies available for thalidomide and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous.
Topics: Aged; Costs and Cost Analysis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lup | 2022 |
Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Topics: Child; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Ery | 2023 |
Apremilast for the Treatment of Concomitant Subacute Cutaneous Lupus Erythematosus and Psoriasis.
Topics: Humans; Lupus Erythematosus, Cutaneous; Psoriasis; Thalidomide | 2022 |
Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Topics: Exanthema; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Thal | 2023 |
Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Thalidomide; Treatment Outcome | 2021 |
One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels.
Topics: Adult; Female; Humans; Incidence; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Mal | 2021 |
High Prevalence of Personality Disorders in Skin-restricted Lupus Patients.
Topics: Adult; Age of Onset; Case-Control Studies; Chi-Square Distribution; Dermatologic Agents; Female; Fra | 2017 |
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study.
Topics: Adult; Age Distribution; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration | 2018 |
Thalidomide and thromboprophylaxis for dermatologic indications: An unmet need for more evidence.
Topics: Drug Tolerance; Humans; Lupus Erythematosus, Cutaneous; Multiple Myeloma; Thalidomide; Venous Thromb | 2018 |
Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation.
Topics: Electric Stimulation Therapy; Female; Ganglia, Spinal; Humans; Immunosuppressive Agents; Lupus Eryth | 2019 |
Efficacy of lenalidomide in refractory lupus pernio.
Topics: Chilblains; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalid | 2013 |
Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
Topics: Adult; Aged; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Recurrence; Retrospe | 2015 |
Thalidomide-induced orofacial neuropathy.
Topics: Adult; Face; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Paresthesia; | 2014 |
Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Topics: Academic Medical Centers; Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Coho | 2016 |
Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
Topics: Adolescent; Adult; Blood Sedimentation; China; Constipation; Dose-Response Relationship, Drug; Exant | 2016 |
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Topics: Adult; Chronic Disease; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cuta | 2016 |
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Topics: Adolescent; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus | 2017 |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Daps | 2017 |
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Topics: Adult; Female; Humans; Lenalidomide; Leukocytes; Lupus Erythematosus, Cutaneous; Lupus Erythematosus | 2012 |
Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Humans; Long-Term Care; Lupus Erythematosus, Cu | 2012 |
Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cut | 2001 |
[Thalidomide therapy of cutaneous lupus erythematosus].
Topics: Adult; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Intrader | 2002 |
Thalidomide experience of a major Australian teaching hospital.
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Dermatologic Agents; Female; Humans; Lupus Erythematosus, | 2002 |
Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosu | 2003 |
[Classification of dermatologic manifestations in lupus erythematosus].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Antimalarials; Clinical Trials as Topic; Dapsone; Dermato | 2003 |
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
Topics: Adult; Electrophysiology; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle A | 2004 |
Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressi | 2005 |
Thalidomide.
Topics: Humans; Lupus Erythematosus, Cutaneous; Thalidomide | 2004 |
Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.
Topics: Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Thalidomide | 2004 |
Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
Topics: Adult; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; Immunosuppressive Agents | 2005 |
[Thalidomide therapy for discoid lupus erythematosus].
Topics: Amenorrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Retrospective | 2006 |
Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide.
Topics: Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle Aged; Myocardial In | 2007 |
Thalidomide and sensory neurotoxicity: a neurophysiological study.
Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou | 2008 |
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.
Topics: Adult; Drug Tolerance; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Nervous Sy | 1997 |
Pustuloderma during cutaneous lupus treatment with thalidomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Drug Eruptions; Female; Humans; | 1999 |
[Thalidomide and thrombosis].
Topics: Adult; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; | 2000 |
Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; C-Reactive Protein; Complement System Proteins; Enzyme-Linked Immuno | 2000 |
[Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases].
Topics: Adult; Aged; Antimalarials; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Mal | 2000 |
Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus.
Topics: Humans; Lupus Erythematosus, Cutaneous; Risk Assessment; Thalidomide; Thrombosis | 2002 |